Previous Close | 1.0200 |
Open | 1.0200 |
Bid | 1.0000 x 4000 |
Ask | 1.1400 x 900 |
Day's Range | 0.9810 - 1.0400 |
52 Week Range | 0.9600 - 12.8800 |
Volume | |
Avg. Volume | 171,216 |
Market Cap | 26.289M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -13.7450 |
Earnings Date | Nov 15, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.25 |
Conference call and webcast today at 4:30pm Eastern/1:30pm PacificMENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the first quarter ended March 31, 2022. Business update Completed assessment of manufacturing processes and product design for manufac
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
MENLO PARK, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report first quarter financial results on Tuesday, May 10, 2022, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Ti